Comprehensive medication guide to Thyrogen Kit including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Medicare Part B covers 80% after the annual deductible when administered in outpatient settings; commercially insured patients vary widely by plan, with prior authorization almost universally required. The Thyrogen Co-Pay Assistance Program covers up to $1,000 of out-of-pocket costs per year for eligible commercially insured patients.
Estimated Cash Pricing
$4,000–$5,500 retail for a complete two-injection kit; no generic available. No significant discount coupon programs apply — Thyrogen is a specialty biologic billed primarily through medical insurance (not pharmacy benefit). The Sanofi Patient Connection program may provide it at no cost for eligible uninsured patients.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Thyrogen Kit is the brand name for thyrotropin alfa — a recombinant human thyroid-stimulating hormone (rhTSH) produced by Genzyme Corporation, a Sanofi company. First approved by the FDA in December 1998, Thyrogen Kit is a specialty injectable biologic used in patients with well-differentiated thyroid cancer who have previously undergone a near-total or total thyroidectomy.
Thyrogen Kit has two FDA-approved indications: (1) as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine (RAI) imaging in the follow-up of patients with well-differentiated thyroid cancer, and (2) as adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients without evidence of distant metastatic thyroid cancer.
Unlike most medications, Thyrogen Kit is not dispensed at retail pharmacies. It is a specialty biologic administered by a healthcare provider in a clinical setting — such as an endocrinologist's office, nuclear medicine department, or hospital outpatient facility — as a two-injection intramuscular protocol over two consecutive days.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Thyrogen Kit (thyrotropin alfa) is a laboratory-made version of thyroid-stimulating hormone (TSH) — the signal your pituitary gland normally sends to thyroid cells. When injected, thyrotropin alfa binds to TSH receptors on remaining thyroid tissue and well-differentiated thyroid cancer cells, activating them to take up iodine, produce thyroglobulin (Tg), and secrete thyroid hormones (T3 and T4).
This activation makes thyroglobulin blood tests more sensitive (Tg is released when TSH is high), and makes radioiodine scans and ablation more effective (thyroid cells take up iodine only when TSH-stimulated). The key advantage over the traditional thyroid hormone withdrawal (THW) method: Thyrogen provides this TSH stimulation exogenously, so patients can remain on their thyroid hormone replacement therapy throughout the protocol and avoid the weeks of debilitating hypothyroidism that THW requires.
The two-injection protocol (0.9 mg IM on Day 1, 0.9 mg IM on Day 2) achieves peak TSH stimulation around 72 hours after the final injection, which is timed precisely with Tg blood draw (Day 4-5), radioiodine administration (Day 3), and diagnostic scanning (Day 5) as applicable.
0.9 mg — intramuscular injection (lyophilized powder)
Single-dose vial reconstituted with 1.2 mL Sterile Water for Injection; administered as two injections 24 hours apart
As of 2026, Thyrogen Kit is not on the FDA's active drug shortage list. However, this specialty biologic comes with significant access complexity. It is not stocked at retail pharmacies — it flows through specialty pharmacy networks, hospital pharmacy systems, and manufacturer-authorized distributors. Access challenges most commonly arise from insurance prior authorization delays (2–4 weeks), specialty pharmacy sourcing lead times (1–2 weeks), and scheduling backlogs at nuclear medicine facilities.
Thyrogen Kit has a history of shortage — a significant multi-year shortage occurred from approximately 2009 to 2012 after a viral contamination was found at Genzyme's Boston manufacturing facility. The shortage was resolved after manufacturing issues were corrected, but it highlighted the systemic vulnerability of a complex biologic with a single manufacturer and no generic alternative.
Patients can use medfinder to locate specialty pharmacies and facilities near them that have Thyrogen Kit available. medfinder contacts pharmacies on your behalf so you don't spend hours making individual calls. The ThyrogenONE support line (1-888-497-6436) is also a key resource for locating current stock.
Thyrogen Kit is not a controlled substance, so there are no special DEA prescribing requirements. However, the FDA prescribing label specifies that Thyrogen should be used by physicians knowledgeable in the management of thyroid cancer patients. In practice, this means the prescribers are typically thyroid cancer specialists with experience coordinating the multi-step Thyrogen protocol.
Endocrinologists — primary prescribers for Thyrogen; manage thyroid cancer surveillance protocols
Nuclear medicine physicians — frequently administer Thyrogen and coordinate with endocrinologists
Medical oncologists — especially at thyroid cancer centers or NCI-designated cancer centers
Nurse practitioners and physician assistants — when credentialed and working within the scope of a thyroid cancer practice
Telehealth endocrinologists can evaluate patients, write Thyrogen prescriptions, and initiate insurance authorization remotely — but the actual injections must be given in person at a clinical facility. Patients in areas with limited local specialist access may begin with a telehealth consultation and then travel to a nuclear medicine facility for the two-day injection protocol and scanning.
No. Thyrogen Kit (thyrotropin alfa) is not a controlled substance. It is not classified under any DEA schedule and has no potential for abuse, dependence, or diversion. It is not a narcotic, stimulant, sedative, or any other class of drug that the DEA regulates.
Although Thyrogen Kit requires a physician's prescription and can only be administered by a healthcare provider in a clinical setting, these restrictions relate to its nature as a specialty injectable biologic — not to any controlled substance status. There are no refill restrictions, prescription transfer limitations, or early refill prohibitions associated with controlled substance scheduling.
Insurance prior authorization is almost always required due to the high cost of this specialty biologic ($4,000–$5,500 per treatment course), but this is a coverage requirement, not a controlled substance regulation. Patients do not need any special federal or state documentation beyond a standard prescription to receive Thyrogen.
The most common side effects reported in clinical trials (≥1% of patients) include:
Nausea (approximately 10.5% of patients)
Headache (approximately 7.3% of patients)
Fatigue
Vomiting
Dizziness
Paresthesia (tingling or numbness)
Injection site discomfort (pain, redness at IM injection site)
Thyrogen-induced hyperthyroidism — significant TSH-driven thyroid hormone elevation in patients with residual thyroid tissue or functional metastases; can be fatal in high-risk patients
Stroke — post-marketing reports in female patients within 72 hours of administration; relationship not fully established
Neurological events — hemiplegia or hemiparesis in patients with CNS metastases, 1–3 days post-injection
Sudden rapid tumor enlargement — in patients with distant metastatic thyroid cancer, within 12–48 hours; may cause dyspnea, stridor, or dysphonia
Anaphylaxis — possible with repeated use
Know what you need? Skip the search.
Thyroid Hormone Withdrawal (THW)
Traditional protocol of stopping levothyroxine for 4–6 weeks to raise endogenous TSH naturally. Clinically effective but associated with severe hypothyroid symptoms (fatigue, cognitive fog, depression, weight gain). No drug cost, but significant quality-of-life impact.
Liothyronine (T3)-Assisted Withdrawal
Modified THW protocol using short-acting liothyronine (Cytomel) to shorten withdrawal period to approximately 2 weeks versus 4–6 weeks for levothyroxine withdrawal. Still involves symptomatic hypothyroidism but shorter duration.
Levothyroxine (ongoing suppression)
Levothyroxine is the thyroid hormone replacement that patients take continuously after thyroidectomy. It is not an alternative to Thyrogen for surveillance stimulation — rather, it is the background therapy that Thyrogen allows patients to continue during testing, unlike thyroid hormone withdrawal.
Prefer Thyrogen Kit? We can find it.
Radioiodine (I-131)
moderateThyrogen is frequently used IN COMBINATION with RAI; all RAI contraindications (pregnancy, breastfeeding, iodine excess) apply when the two are used together. High dietary or medicinal iodine intake reduces RAI effectiveness.
Amiodarone
majorHeart medication with very high iodine content (~37% by weight). Can suppress RAI uptake for months to years after discontinuation; significantly impairs RAI treatment effectiveness when used in combination with Thyrogen.
Iodinated contrast dyes (CT, angiography)
moderateRecent CT scans with iodinated contrast can temporarily reduce RAI uptake; a waiting period of several weeks to months is typically recommended before RAI administration.
Oral contraceptives
moderatePost-marketing reports of stroke in female patients receiving Thyrogen who were also taking oral contraceptives. Causal relationship not established, but OCP use is noted as a potential contributing risk factor for stroke.
Cardiac medications (general)
moderatePatients with underlying heart disease receiving cardiac medications are at elevated risk for Thyrogen-induced hyperthyroidism complications. Hospitalization for Thyrogen administration and monitoring should be considered.
Thyrogen Kit (thyrotropin alfa) represents one of the most meaningful improvements in the quality-of-life of thyroid cancer patients in the past three decades. By enabling thyroglobulin testing and radioiodine procedures without requiring the physically and emotionally grueling thyroid hormone withdrawal protocol, it has transformed what annual surveillance looks like for hundreds of thousands of patients.
The primary access challenges with Thyrogen Kit in 2026 are not about drug efficacy or shortage — the drug is available. The challenges are structural: insurance prior authorization requirements, specialty pharmacy logistics, and the need for clinical coordination across multiple specialties. Patients and providers who plan ahead, start the authorization process early, and maintain relationships with specialty pharmacy partners have the best outcomes.
If you are a thyroid cancer patient preparing for your next surveillance scan or ablation and need help locating Thyrogen Kit at a facility near you, medfinder contacts specialty pharmacies on your behalf to find available supply. Call ThyrogenONE at 1-888-497-6436 for manufacturer support and savings program enrollment.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini